Zydus Pharmaceuticals (USA) Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zydus Pharmaceuticals (USA) Inc.
At The Edge Of The Cliff: Five Blockbuster Drugs Set To Lose US Patent Exclusivity In 2023
With the advent of 2023, comes the start of the industry’s next patent cliff, with five products that reached billions in sales at their peak set to lose US patent exclusivity during the year. Scrip takes a look into how the affected big pharma firms are preparing for anticipated market erosion and which generic and biosimilar companies are positioned to benefit the most.
Keeping Track: Spectrum Submits Poziotinib; US FDA Approves Daré’s Xaciato, Expands Heron Zynrelef Label
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
How DOJ Built Its Generic Price Fixing Case: Cooperating Witnesses At Competitors
Former sales and marketing exec at Taro Pharmaceuticals is latest exec charged with participating in price fixing conspiracies.
AndroGel Competitors Enter US After Perrigo’s Exclusivity Expires
Following the expiry of Perrigo’s 180-day exclusivity for its generic version of AndroGel, firms including Lupin and Teva have launched their own generic testosterone 1.62% gels in the US.
- Generic Drugs
- OTC, Consumer
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.